))
S2E04: Alex Harding - Biotech Investing, Entrepreneurship and Drug Pricing
Manage episode 313065883 series 3257692
Sharif Vakili द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Sharif Vakili या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।
Is it possible for market competition to lower drug prices in pharma, or are we resigned to ever-increasing prices with each new biotech innovation? Dr. Alex Harding, biotech venture capitalist at Atlas Ventures, VP of Business Development and Corporate Strategy at Remix Therapeutics and MGH internal medicine physician, joins for a multifaceted conversation around drug pricing, being a practicing physician in biotech VC, and life sciences entrepreneurship. A contributor to the biotech newsletter the Timmerman Report, Alex discusses his recent report on the disruptive drug discovery startup, EQRx, that is contending to radically lower drug prices. Join for a thought-provoking conversation around the consequences of EQRx’s business model and the challenges with market-based drug pricing reform in the United States.
This episode marks the end of the summer interseason. The Doctor is Out will be back in a few months after a short break.
36 एपिसोडस
साझा करें
